Pleiotropic effects of HMG-CoA reductase inhibitors

被引:207
|
作者
Werner, N [1 ]
Nickenig, G [1 ]
Laufs, U [1 ]
机构
[1] Univ Saarlandes Kliniken, Med Klin & Poliklin, D-66421 Homburg, Germany
关键词
HMG CoA reductase inhibitiors; hypercholesterolemia; pleiotropic effects; review;
D O I
10.1007/s003950200000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
HMG CoA reductase inhibitiors (statins) have been shown to be effective lipid lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels. This review summarizes the current evidence and the molecular mechanisms of the direct effects of statins on plaque stability, inflammation, endothelial function, oxidative stress, thrombosis and stroke. Furthermore, recent data on the effects of statins on bone marrow, bone density and dementia are described. In summary, statins have emerged as a novel and powerful tool to study cardiovascular biology, including protein isoprenylation, small G protein function, leukocyte activity and endothelial progenitor cells. These pleiotropic properties of statins may have important clinical implications in addition to lowering serum cholesterol.
引用
收藏
页码:105 / 116
页数:12
相关论文
共 50 条
  • [1] Pleiotropic effects of the HMG-CoA reductase inhibitors
    Mihos, Christos G.
    Santana, Orlando
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2011, 4 : 261 - 271
  • [2] Importance of Rac1 Signaling Pathway Inhibition in the Pleiotropic Effects of HMG-CoA Reductase Inhibitors
    Rashid, Mamunur
    Tawara, Shunsuke
    Fukumoto, Yoshihiro
    Seto, Minoru
    Yano, Kazuo
    Shimokawa, Hiroaki
    CIRCULATION JOURNAL, 2009, 73 (02) : 361 - 370
  • [3] Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors
    Duplaga, BA
    ANNALS OF PHARMACOTHERAPY, 1999, 33 (11) : 1224 - 1227
  • [4] Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
    Franco Bernini
    Andrea Poli
    Rodolfo Paoletti
    Cardiovascular Drugs and Therapy, 2001, 15 : 211 - 218
  • [5] Atorvastatin: A step ahead for HMG-CoA reductase inhibitors
    Black, DM
    PERFUSION, 1996, 9 (04): : 140 - 142
  • [6] Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin
    Bernini, F
    Poli, A
    Paoletti, R
    CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (03) : 211 - 218
  • [7] Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
    Cho, Yongin
    Choe, EunYeong
    Lee, Yong-ho
    Seo, Ji Won
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (04): : 482 - 488
  • [8] HMG-COA REDUCTASE INHIBITORS - A LOOK BACK AND A LOOK AHEAD
    DAVIGNON, J
    MONTIGNY, M
    DUFOUR, R
    CANADIAN JOURNAL OF CARDIOLOGY, 1992, 8 (08) : 843 - 864
  • [9] Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia
    Prat, H
    Román, O
    Pino, E
    REVISTA MEDICA DE CHILE, 1999, 127 (03) : 286 - 294
  • [10] Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors
    Pfefferkorn, Jeffrey A.
    Choi, Chulho
    Song, Yuntao
    Trivedi, Bharat K.
    Larsen, Scott D.
    Askew, Valerie
    Dillon, Lisa
    Hanselman, Jeffrey C.
    Lin, Zhiwu
    Lu, Gina
    Robertson, Andrew
    Sekerke, Catherine
    Auerbach, Bruce
    Pavlovsky, Alexander
    Harris, Melissa S.
    Bainbridge, Graeme
    Caspers, Nicole
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (16) : 4531 - 4537